MedReleaf Australia has launched four new products into its concession scheme, established in 2021 to provide easier patient access to its plant-based medicines.
The MedReleaf Concession Scheme gives Australian doctors the ability to prescribe medicinal cannabis products to disadvantaged patients who might not otherwise be able to afford therapy.
It is available to pensioner concession, commonwealth seniors, health care and veteran card holders.
As a result of its success, MedReleaf is increasing the range available under the scheme, adding three IndiMed oils and an IndiMed balanced dried flower product.
The company now has 28 finished branded pharmaceutical products in its range.
CEO Russell Harding said: “It is pleasing to assist financially disadvantaged patients to gain access to medical cannabis treatments in Australia – products manufactured to the highest quality EU-GMP standards.
“In the absence of PBS-listed medical cannabis, both MedReleaf and our exclusive supply partner Aurora are proud to assist concession card holders in this way.”
Executive director Nathan Davis added: “Our ongoing vision is to be the partner of choice for doctors prescribing medical cannabis to patients. The MedReleaf Concession Scheme is a continuation of this.
“We listened to our doctors who were in search of more formulations to help their concession card holders.
“We will continue to develop products and invest in both our concession program and our general range available for doctors to improve the quality of life of their patients.”